⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 27, 2024Research and Practice in Thrombosis and HaemostasisOpen Access

Is lupus anticoagulant testing with dilute Russell’s viper venom clotting times reliable in the presence of inflammation?

Michaël Hardy Émilie Catry Marie Pouplard Thomas Lecompte François Mullier

View Full Paper

Ask AI

Bookmark

Share

Abstract

Testing for lupus anticoagulant (LA) is not recommended in case of inflammation as C-reactive protein (CRP) can interfere

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hardy et al. (2024) studied this question.

synapsesocial.com/papers/68e5ed47b6db643587581ad9 https://doi.org/10.1016/j.rpth.2024.102536

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Diluted Russell Viper Venom Test for Lupus Anticoagulant Detection in Pregnancy PopulationCase-Control Study · 2026
2Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by AnticoagulantsOriginal Research · 2026
3The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulantsOriginal Research · 1986 · 422 citations
4Comparison of two algorithms of APTT-based lupus anticoagulant assay, two Dilute Russell viper venom time reagents, and silica clotting timeOriginal Research · 2026
5Impact of different preanalytical conditions on results of lupus anticoagulant testsother · 2019 · 14 citations

More related papers

The role of different aPL subpopulations in the lupus anticoagulant phenomenon2026
Interference of Lupus Anticoagulant Causing Anti-Prothrombin and Anti-Beta-2-Glycoprotein I Antibodies on INR Measurements: Comparative Analysis of INR Methods2024
The challenges of lupus anticoagulants2016

More from Research and Practice in Thrombosis and Haemostasis

The first month after direct oral anticoagulants: a window of vulnerabilitySat,
OC 41.1 Recurrent venous thromboembolism during extended apixaban therapy for cancer-associated thrombosis: clinical presentation and short-term outcomes. Insights from the API-CAT proepective randomised double-blind trialTue,